News

Next Gen CAR-T Platform a Potential Game Changer – Special Report by Independent Investment Research (IIR)

July 8, 2020

Next Gen CAR-T Platform a Potential Game Changer – Special Report by Independent Investment Research (IIR)

Independent Investment Research (IIR) recently authored a special investment report on pre-clinical oncology company Prescient Therapeutics (ASX: PTX) which gives great insight into the company and the progress they’ve made in recent months. 

Independent Investment Research (IIR) recently authored a special investment report on pre-clinical oncology company Prescient Therapeutics (ASX: PTX) which gives great insight into the company and the progress they’ve made in recent months. 

The report explores key information of interest to potential investors including an investment profile, SWOT analysis, company overview, financial position, acquisitions, technologies as well as recent news.

The report also goes into great detail about PTX as a company and gives an in-depth explanation of their current technologies and projects. It also includes their recent expansion in the CAR-T market, with the acquisition of the exclusive global licence of a next generation CAR-T platform from the University of Pennsylvania. 

 

The key highlights of the report include:

Why the ‘Next Gen CAR-T Platform’ could be a Potential Game Changer

  • According to IIR, the acquisition of Next Generation CAR-T Platform from the University of Pennsylvania (Upenn) could be a potential game changer. PTX intends to use these licences and technology to build OmniCAR, a next generation cell therapy platform.
  • The acquisition compliments their collaboration with Carina Biotech to develop Carina’s CAR-T technologies for the treatment of solid tumours.

 

Clinical Development

  • IIR expects that  Prescient Therapeutics will seek to deliver a proof of concept for the OmniCAR Platform swiftly – likely on known and validated targets in blood cancers first, before moving on to solid cancers. 
  • “The recent collaboration with Carina Biotech provides a convenient pathway for testing on new solid tumour targets,” states the report.

Financial Position

  • The company generated a loss of $1.7m in 1H’20, a slight increase from the $1.6m loss in 1H’19. 
  • At 31 March 2020, the company had $8.2m in cash reserves. 
  • At 31 March, the company had sufficient capital to operate for a further 18 months.

 

Investment view

  • IRR states thatPTX provides a unique investment opportunity on the domestic market given the company is the only ASX-listed company with UIR technology.’
  • The report also quotes ‘We acknowledge that the OmniCAR platform is in the early stages of development and the development of the platform will encounter its own unique challenges.’

 

Read the full report here.

 

Reach Markets have been engaged by PTX to assist with private investor management.

 


General Advice Warning

Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG) including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.

Please click here to read our full warning.

Live Investor Briefing

Discover the key projects shaping the iron ore industry

Leave a comment